Ambroxol

Research use only, not for human use.

Ambroxol is indicated as "secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport.

Ambroxol is indicated as "secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport. It promotes mucus clearance, facilitates expectoration and eases productive cough, allowing patients to breathe freely and deeply.(In Vitro):Ambroxol (NA-872; 1, 3, 4, 5 mM for 12 consecutive days in drinking water) results in increased brain glucocerebrosidase activity in wild-type mice, transgenic mice expressing the heterozygous L444P mutation in the murine glucocerebrosidase 1 gene, and transgenic mice overexpressing human α-synuclein.

——

Ambroxol (NA-872; 1, 3, 4, 5 mM for 12 consecutive days in drinking water) results in increased brain glucocerebrosidase activity in wild-type mice, transgenic mice expressing the heterozygous L444P mutation in the murine glucocerebrosidase 1 gene, and transgenic mice overexpressing human α-synuclein.

NA 872

Metabolic Enzyme/Protease

P450

CYP3A

Other Indications

——

18683-91-5

378.1

C13H18Br2N2O

>98% (HPLC)

Soluble in DMSO

O[C@H]1CC[C@H](NCC2=CC(Br)=CC(Br)=C2N)CC1

Cyclohexanol, 4-(((2-amino-3,5-dibromophenyl)methyl)amino)-, trans- (9CI)

(-20℃)

With Ice Pack

≥ 2 years